{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T14:00:58Z","timestamp":1777557658317,"version":"3.51.4"},"reference-count":29,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Technology &amp; Therapeutics"],"published-print":{"date-parts":[[2012,7]]},"abstract":"<jats:sec>\n                    <jats:title>Aim\/Introduction:<\/jats:title>\n                    <jats:p>\n                      Subsample analysis was performed to examine whether dose optimization of insulin glargine (Lantus\n                      <jats:sup>\u00ae<\/jats:sup>\n                      ; sanofi-aventis K.K., Tokyo, Japan) contributed to achieving a target glycosylated hemoglobin (HbA1c) (&lt;7.0%) by using the data from the Add-on Lantus to Oral Hypoglycemic Agents (ALOHA) study, a 24-week observational study of Japanese type 2 diabetes patients. We investigated the conditions of optimal dose titration by identifying patient background of dose-achiever and non-achiever subgroups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Subjects and Methods:<\/jats:title>\n                    <jats:p>\n                      The insulin-naive patients (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      =3,180) were categorized into four groups depending on their HbA1c and insulin glargine dose at 24 weeks: patients with HbA1c &lt;7.0% and dose &lt;8.5\u2009U\/day (Group 1), HbA1c &lt;7.0% and dose \u22658.5\u2009U\/day (Group 2), HbA1c \u22657.0% and dose &lt;8.5\u2009U\/day (Group 3), and HbA1c \u22657.0% and dose \u22658.5\u2009U\/day (Group 4).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The greatest reduction in HbA1c was observed in Group 2 (\u20132.7%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001 vs. Group 3 or 4). Fasting plasma glucose (FPG) in Group 2 at 24 weeks (113.3\u2009mg\/dL) was significantly lower than in either Group 3 or 4 (135.4\u2009mg\/dL and 150.0\u2009mg\/dL, respectively;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001 for both). The starting dose and the change of insulin glargine dose were significantly greater in Group 2 than in Group 3 (0.142 vs. 0.086\u2009U\/kg\/day [\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001] and +5.0 vs. +1.1\u2009U\/day [\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001], respectively), whereas the baseline HbA1c levels and body mass index were comparable (9.3% vs. 9.4% and 23.5\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      vs. 23.3\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , respectively).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Our results suggest that appropriate starting dosage and subsequent dose adjustment are essential to achieve target HbA1c (&lt;7%) and that the FPG level should be decreased to be 110\u2009mg\/dL or below for this achievement.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/dia.2011.0220","type":"journal-article","created":{"date-parts":[[2012,4,23]],"date-time":"2012-04-23T17:00:29Z","timestamp":1335200429000},"page":"635-643","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":24,"title":["Dosing of Insulin Glargine to Achieve the Treatment Target in Japanese Type 2 Diabetes on a Basal Supported Oral Therapy Regimen in Real Life: ALOHA Study Subanalysis"],"prefix":"10.1177","volume":"14","author":[{"given":"Masato","family":"Odawara","sequence":"first","affiliation":[{"name":"Tokyo Medical University","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Ohtani","sequence":"additional","affiliation":[{"name":"sanofi-aventis K.K., Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kadowaki","sequence":"additional","affiliation":[{"name":"The University of Tokyo","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2012,7,1]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.11.3080"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.06.018"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-9025"},{"key":"e_1_3_3_5_2","unstructured":"Japan Diabetes Society: Diabetes Therapeutic Guide. Tokyo: Bunkodo Co. Ltd. 2010."},{"key":"e_1_3_3_6_2","first-page":"897","article-title":"Comparison between long-acting and biphasic insulin analogs in patients with type 2 diabetes: CoDiC\u00ae data analysis [in Japanese]","volume":"58","author":"Kobayashi M","year":"2009","unstructured":"Kobayashi M, , Yamazaki K, , Kanatsuka A. Japanese Diabetes Clinical Data Management Study Group. Comparison between long-acting and biphasic insulin analogs in patients with type 2 diabetes: CoDiC\u00ae data analysis [in Japanese] Shinyaku to Rinsho, 2009; 58:897\u2013904.","journal-title":"Shinyaku to Rinsho"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.22.3.403"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-0435"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2003.11.024"},{"key":"e_1_3_3_10_2","first-page":"458","article-title":"Safety and effectiveness of BOT (Basal supported Oral Therapy) using insulin glargine in Japanese patients with type 2 diabetes\u2013results from post-marketing surveillance of insulin glargine (ALOHA Study) [in Japanese]","volume":"60","author":"Ohtani T","year":"2011","unstructured":"Ohtani T, , Ito T. Safety and effectiveness of BOT (Basal supported Oral Therapy) using insulin glargine in Japanese patients with type 2 diabetes\u2013results from post-marketing surveillance of insulin glargine (ALOHA Study) [in Japanese] Shinyaku to Rinsho, 2011; 60:458\u2013475.","journal-title":"Shinyaku to Rinsho"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.2040-1124.2010.00074.x"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/75.4.800"},{"key":"e_1_3_3_13_2","unstructured":"Development Core Team: R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing 2011."},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-005-0132-0"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2008.00873.x"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.2.254"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-1357"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2006.01881.x"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2006.08.012"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2006.00593.x"},{"key":"e_1_3_3_21_2","first-page":"489","article-title":"Insulin therapy for type 2 diabetes: rescue, augmentation, and replacement of beta-cell function","volume":"70","author":"Mayfield JA","year":"2004","unstructured":"Mayfield JA, , White RD. Insulin therapy for type 2 diabetes: rescue, augmentation, and replacement of beta-cell function. Am Fam Physician, 2004; 70:489\u2013500.","journal-title":"Am Fam Physician"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60762-X"},{"key":"e_1_3_3_23_2","first-page":"591","article-title":"Effectiveness of combination therapy with a sulfonylurea and once-daily insulin glargine in Japanese type 2 diabetic patients\u2013evaluation of the long-term (18 months) results of the combination therapy [in Japanese]","volume":"50","author":"Goto H","year":"2007","unstructured":"Goto H, , Hirose T, , Shimizu T, , Mita T, , Igarashi Y, , Fujitani Y, , Tanaka Y, , Watada H, , Kawamori R. Effectiveness of combination therapy with a sulfonylurea and once-daily insulin glargine in Japanese type 2 diabetic patients\u2013evaluation of the long-term (18 months) results of the combination therapy [in Japanese] Tonyobyo, 2007; 50:591\u2013597.","journal-title":"Tonyobyo"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.2165\/00007256-200030050-00002"},{"key":"e_1_3_3_25_2","first-page":"401","article-title":"CoDiC\u00ae: surveillance of clinical management of diabetes in Japan (2nd report)","volume":"5","author":"Kobayashi M","year":"2007","unstructured":"Kobayashi M, , Yamazaki K, , Kanatsuka A. Japanese Diabetes Clinical Data Management Study Group. CoDiC\u00ae: surveillance of clinical management of diabetes in Japan (2nd report) Jpn J Diabetes Master Clinician, 2007; 5:401\u2013406.","journal-title":"Jpn J Diabetes Master Clinician"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-1278"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802987"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-138-12-200306170-00006"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2010.0170"},{"key":"e_1_3_3_30_2","first-page":"233","article-title":"Safety and effectiveness of biphasic insulin aspart 30 (BIAsp30) in patients with type 2 diabetes (T2D)\u2014IMPROVE Study in Japan [in Japanese]","volume":"37","author":"Kawamori R","year":"2009","unstructured":"Kawamori R, , Kaku K, , Kasuga M, , Kadowaki T, , Kobayashi M, , Satoh J, , Tajima N, , Haneda M, , Shuto Y. Safety and effectiveness of biphasic insulin aspart 30 (BIAsp30) in patients with type 2 diabetes (T2D)\u2014IMPROVE Study in Japan [in Japanese] Jpn Pharmacol Ther, 2009; 37:233\u2013241.","journal-title":"Jpn Pharmacol Ther"}],"container-title":["Diabetes Technology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/dia.2011.0220","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/dia.2011.0220","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/dia.2011.0220","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:19:14Z","timestamp":1777400354000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/dia.2011.0220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["10.1089\/dia.2011.0220"],"URL":"https:\/\/doi.org\/10.1089\/dia.2011.0220","relation":{},"ISSN":["1520-9156","1557-8593"],"issn-type":[{"value":"1520-9156","type":"print"},{"value":"1557-8593","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}